COLLINS HELEN LOUISE (CHIEF MEDICAL OFFICER) sold 16.7% of their position (5K shares) of ENLIVEN THERAPEUTICS, INC. on the open market
Open‑market sale worth $238.4K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 4/22/2026ACC: 0001701247-26-000006
Officer· CHIEF MEDICAL OFFICER
Since Feb 2026
-5K
Net shares
Net seller
$238.4K
Total sold
3
Open market trades
0B · 3S
5
Total transactions
5K acquired · 10K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+5K
Price / share
$2.48
Trade value
$12.40K
% of position
20.0%
4/17/2026
25K→30K
Common Stock
Direct
Shares
−140.00
Price / share
$45.81
Trade value
$6.41K
% of position
0.5%
4/17/2026
30K→29.86K
Common Stock
Direct
Shares
−2.42K
Price / share
$47.39
Trade value
$114.64K
% of position
8.1%
4/17/2026
29.86K→27.44K
Common Stock
Direct
Shares
−2.44K
Price / share
$48.06
Trade value
$117.30K
% of position
8.9%
4/17/2026
27.44K→25K
Total
Net shares
+0.00
Net value
-$225.95K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/17/2026 | M · Option Exercise | +5K | $2.48 | $12.40K | 20.0% | 25K | 30K |
| Common Stock Direct | 4/17/2026 | S · Sale | −140.00 | $45.81 | $6.41K | 0.5% | 30K | 29.86K |
| Common Stock Direct | 4/17/2026 | S · Sale | −2.42K | $47.39 | $114.64K | 8.1% | 29.86K | 27.44K |
| Common Stock Direct | 4/17/2026 | S · Sale | −2.44K | $48.06 | $117.30K | 8.9% | 27.44K | 25K |
| Total | +0.00 | -$225.95K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
5K shares
Shares
−5K
Strike price
2.48
Held after
131.27K
Exercisable
—
4/17/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock5K shares | 4/17/2026 | M · Option Exercise | −5K | 2.48 | — | 131.27K |